Supernus Pharma

SUPN NASDAQ
27.12
-0.31
-1.13%
After Hours: 27.12 0 0.00% 16:08 08/22 EDT
Open
27.49
Prev Close
27.43
High
27.60
Low
26.91
Volume
349.53K
Avg Vol (3M)
485.09K
52 Week High
51.38
52 Week Low
26.90
% Turnover
0.67%
Market Cap
1.42B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Supernus Pharma SUPN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
MORE >

Recently

Name
Price
%Change